MedTrace Logo

A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.

NCT07042100 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 177

Last updated 2026-05-15

No results posted yet for this study

Summary

This is a Phase 1 study of SBO-154 in patients with advanced cancers who are unable to tolerate or have not previously responded to standard therapy available in the country. The study involves multiple doses and takes place at several centers.

Conditions

Interventions

BIOLOGICAL

Dose level (DL)1

Administered IV every 3 weeks

BIOLOGICAL

DL2

Administered IV every 3 weeks

BIOLOGICAL

DL3

Administered IV every 3 weeks

BIOLOGICAL

DL4

Administered IV every 3 weeks

BIOLOGICAL

DL5

Administered IV every 3 weeks

Sponsors & Collaborators

  • Sun Pharma Advanced Research Company Limited

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-12
Primary Completion
2028-08-31
Completion
2030-08-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07042100 on ClinicalTrials.gov